ATH ATH アテネ・ホ―ルディング



symbol ATH
会社名 Athene Holding Ltd (ATH アテネ・ホ―ルディング)
業種 保険_生命_健康   金融(Financials)
概要 事業概要 Athene Holding Ltd is a retirement services company. The Company issues reinsures and acquires retirement savings products across the United States and the District of Columbia. It operates through the Retirement Services segment. Retirement Services is comprised of its United States and Bermuda operations which issue and reinsure retirement savings products and institutional products. Retirement Services has retail operations which provide annuity retirement solutions to its policyholders. Retirement Services segment also has reinsurance operations which reinsure multi-year guaranteed annuities fixed indexed annuities traditional one-year guarantee fixed deferred annuities immediate annuities and institutional products from its reinsurance partners. In addition its institutional operations including funding agreements and pension risk transfer (PRT) obligations are included in its Retirement Services segment. Its products include individual annuities and group annuities.  アテ―ネ―・ホ―ルディングはバミュ―ダ籍の保険持株会社。子会社を通じて、個人と組織に対し退職貯蓄商品の発行、再保証、取得を通じ、退職後の資金管理などの退職者サ―ビスの提供に従事する。流動性が低い負債とパフォ―マンスの良いポ―トフォリオに投資をして、株主に利益を与える。社は米国とバミュ―ダで事業を展開。  Athene Holding Ltd. is engages in the provision of retirement services. The firm issues, reinsures and acquires retirement savings products and institutional products. Its products include individual and group annuities. The company was founded by James R. Belardi and Frank L. Gills in May 2009 and is headquartered in Pembroke, Bermuda.
本社所在地 96 Pitts Bay Road Pembroke HM08 BMU
代表者氏名 James Richard Belardi
代表者役職名 Chairman of the Board Chief Executive Officer Chief Investment Officer
電話番号 +1 441-279-8400
設立年月日 2008年
市場名 NYSE(ニューヨーク証券取引所)
従業員数 1275人
EBITDA EBITDA(百万ドル) 1757.00000
時価総額 時価総額(百万ドル) 7621.93300
売上高 売上高(百万ドル) 6723.00000
企業価値(EV) 企業価値(EV)(百万ドル) 5699.93300
当期純利益 当期純利益(百万ドル) 1053.00000
決算概要 決算概要 BRIEF: For the fiscal year ended 31 December 2018 Athene Holding Ltd revenues decreased 22% to $6.72B. Net income before extraordinary items decreased 22% to $1.05B. Revenues reflect Corporate and Other segment decrease of 88% to $44M. Net income also reflects Reinsurance assumed increase from $37M to $1.03B (expense) Change in unrealized gains or losses decrease from $107M (income) to $143M (expense).



   The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings  2020/08/05 11:35:15 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD ) (FDA approved the emergency use of Abiomed's Impella heart pump in combination with an oxygen machine to treat Covid-19 patients who suffer heart and lung failure) Allovir Inc (NASDAQ: ALVR ) (IPOed Thursday) Alterity Therapeutics Ltd (NASDAQ: ATHE ) ( announced positive preclinical data for its lead drug in Multiple System Atrophy) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Cardiff Oncology Inc (NASDAQ: CRDF ) Cocrystal Pharma Inc (NASDAQ: COCP ) (announced the publication of positive preclinical animal studies of coronavirus antiviral compounds in a medical journal) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Hologic, Inc. (NASDAQ: HOLX ) Inari Medical Inc (NASDAQ: NARI ) Inozyme Pharma Inc (NASDAQ: INZY ) Quidel Corporation (NASDAQ: QDEL ) Renalytix AI PLC (NASDAQ: RNLX ) Sorrento Therapeutics Inc (NASDAQ: SRNE ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Varian Medical Systems, Inc. (NYSE: VAR ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 4) Pandion Therapeutics Holdco LLC (NASDAQ: PAND ) Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) Stocks In Focus Novavax Announces Positive Phase 1 Data For Coronavirus Vaccine Novavax, Inc. (NASDAQ: NVAX ) announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID 19 vaccine NVX CoV2373 with and without Matrix M adjuvant, which showed the investigational vaccine was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.
   Athene Holding Ltd. Reports Second Quarter 2020 Results  2020/08/05 10:30:00 Business Wire
PEMBROKE, Bermuda--(BUSINESS WIRE)--Athene Holding Ltd. Reports Second Quarter 2020 Results
   Alterity's stock nearly triples on heavy volume after update on study of treatment for MSA, Parkinson's  2020/08/04 13:07:11 MarketWatch
Shares of Alterity Therapeutics Ltd. undefined nearly tripled (up 173%) toward a 3-year high on heavy volume in premarket trading Tuesday, after the…
   Alterity Therapeutics Shares Surge As Company Says Animal Testing Data Positive For MSA Drug  2020/08/04 06:33:24 Benzinga
The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE ) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday. What Happened: The surge came as Alterity Therapeutics reported positive data from an animal testing of ATH434 — its leading drug candidate for Multiple System Atrophy, a Parkinsonian disorder. The new data "independently confirm and extend previous … Full story available on
   Alterity Therapeutics : New data independently confirms and extends laboratory findings and expands safety profile of ATH434 | MarketScreener  2020/08/04 00:12:13 MarketScreener
Alterity Therapeutics today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 has been selected for presentation at the 2020 International… | August 4, 2020

 関連キーワード  (保険_生命_健康 米国株 ATH アテネ・ホ―ルディング ATH )


 twitter  (公式ツイッターやCEOツイッターなど)